Compass pathways stock forecast.

Aug 22, 2023 · COMPASS Pathways-stock; ... Compass Pathways has an average price target of $56.82 with a high of $120.00 and a low of $21.00. ... Some analysts will also offer forecasts for metrics like growth ...

Compass pathways stock forecast. Things To Know About Compass pathways stock forecast.

COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the …Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? Wall Street might have the timing wrong, but their hopes aren't misplaced. Alex Carchidi | Jul 1, 2023The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ...The COMPASS Pathways plc stock forecast for tomorrow is $ 5.02, which would represent a -4.68% loss compared to the current price. In the next week, the price of CMPS is expected to decrease by -2.62% and hit $ 5.13. As far as the long-term COMPASS Pathways plc stock forecast is concerned, here’s what our predictions are currently suggesting.

The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...1 de jul. de 2023 ... While Compass Pathways' (CMPS 2.17%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by ...

TipRanksSee COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

COMPASS Pathways (CMPS) Insider Trading Activity 2023. S&P 500 4,559.34. DOW 35,390.15. QQQ 389.51. Turned down for a loan, business owners look to family and even crowdsourcing to get money to grow. [Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad) 13 crew members missing after a cargo ship …Compass Pathways Plc stock forecasts for 2023-2027. Date: Open Price: Close Price: Change: Compass Pathways Plc Stock Forecast for 2023: January 2023: 2.04: 1.02-50% ...People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.06:48 PM ET 11/23/2020. Atai Life Sciences, a company that backs Compass Pathways ( CMPS) and other psychedelic drug developers, said Monday that it had closed a $125 million funding round, the ...Stock Price Forecast. The 9 analysts offering 12-month price forecasts for Compass Inc have a median target of 2.70, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate ...Web

21.61M. MSFT. 377.43. -0.11%. 9.38M. View today's Compass Pathways Plc stock price and latest CMPS news and analysis. Create real-time notifications to follow any changes in the live stock price.

What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...

Compass Pathways Plc - ADR Stock Price Forecast, "CMPS" Predictons for2023. Markets; Forecast . Crypto Forecasts; Top 5 Crypto forecasts; Tether Usdt forecast; ... Compass Pathways Plc - ADR Stock Forecast and Price Prognosis Data for 2023 . History; Forecast; Data; Market; Q&A; Comments; Buy CRYPTOApr 20, 2023 · With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ... CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings data on November 2nd, 2023. The reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted …WebLONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...Stock Price Forecast. The 9 analysts offering 12-month price forecasts for Compass Inc have a median target of 2.70, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate ... *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. COMPASS Pathways Analyst Opinions. All. All ...4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price.

View Our Latest Research Report on COMPASS Pathways. COMPASS Pathways Price Performance. COMPASS Pathways stock opened at $6.01 on Friday. The firm has a market cap of $372.02 million, a P/E ratio of -2.32 and a beta of 2.56. The stock’s 50 day moving average is $6.75 and its 200 day moving average is $7.90.While Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months.WebHow to buy COMPASS Pathways PLC stock on Stash. 1. Enter the amount you'd like to invest in COMPASS Pathways PLC stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.Latest CMPS News. View. COMPASS Pathways (CMPS, $5.98) entered Downtrend as Momentum indicator drops below 0 level on Nov 30, 2023. Tickeron - Stocks • 3 days ago. Compass Pathways to participate in upcoming Evercore investor conference. Globe Newswire • 10 days ago.Psychedelics biotech giant COMPASS Pathways (NASDAQ:CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group ...

The Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744. With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...

View Our Latest Research Report on COMPASS Pathways. COMPASS Pathways Price Performance. COMPASS Pathways stock opened at $6.01 on Friday. The firm has a market cap of $372.02 million, a P/E ratio of -2.32 and a beta of 2.56. The stock’s 50 day moving average is $6.75 and its 200 day moving average is $7.90.Nov 29, 2023 · About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. COMPASS Pathways Plc American Depository Shares (CMPS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant ... COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with...Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...Compass Pathways Stock Performance Analysis: August 4, 2023 On August 4, 2023, the stock performance of Compass Pathways (CMPS) was closely watched by investors and analysts. As per the data sourced from CNN Money, let’s delve into the key figures and analyze the implications for the company.Compass, Inc. (NYSE:COMP) announced its quarterly earnings data on Monday, November, 6th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.35 billion.Web47.29. -1.64%. 4.73M. Find the latest Compass Pathways Plc (CMPS) stock forecast, 12-month price target, predictions and analyst recommendations.WebNonetheless, Atai remains one of the leaders in the psychedelics segment of the biotech industry, and it holds a 22.4% stake in Compass Pathways, which is one of the other leaders. So if Compass ...WebCompare with up to 5 Stocks. On Thursday 11/30/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.20 on NAS. Compared to the opening price on Thursday 11/30/2023 on NAS ...

For COMPASS Pathways plc stock forecast for 2023, 2 predictions are offered for each month of 2023 with average COMPASS Pathways plc stock forecast of $5.33, a high forecast of $5.36, and a low forecast of $5.3. The average COMPASS Pathways plc stock forecast 2023 represents a 0.88% increase from the last price of $5.28499984741211.

5.01 Today ||| 52-Week Range 11.48 -26.03% Year-to-Date Quote Profile News Charts Forecasts Financials Shareholders Competitors vs. Health Technology News Chart Latest CMPS News | Press Releases...

3 พ.ค. 2564 ... Did you miss out on being an early investor in the Cannabis Boom? Investing in Compass Pathways stock ($CMPS) may be your golden ticket.Find the latest analyst research for COMPASS Pathways Plc American Depository Shares (CMPS) at Nasdaq.com.WebUK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the company’s pivotal Phase III trials, the first-ever Phase III psilocybin therapy trial and the final studies prior to market approval. With the treatment’s …9 พ.ย. 2564 ... Compass Pathways CEO on mushroom-based therapy for depression ... Global Business and Financial News, Stock Quotes, and Market Data and Analysis.Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. ... Analyst Forecast. The ...The current Compass Pathways PLC [ CMPS] share price is $6.10. The Score for CMPS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. CMPS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels. US20451W1018. Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom. Show more.In August 2023 COMPASS Pathways announced a major private placement that initially eased concerns regarding group’s cash runway. Find out why CMPS stock is a Sell.In the same quarter last year, COMPASS Pathways's earnings per share (EPS) was -$0.44. COMPASS Pathways is expected to release next earnings on 02/26/2024, with ...Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years.

What happened. Compass Pathways ( CMPS 6.18%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...WebCompass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore. CMPS - COMPASS PATHWAYS PLC. AMERICAN DEPOSITORY SHARES. HOME · Internacional · Stocks ... ASSINATURAS PLANO BULL MÓDULO FORECAST. STATUS INVEST Política de ...Compass Pathways (CMPS) buy sell technical analysis & forecast predictions with share price targets for today short term. Compass Pathways (CMPS) Share trades in NASDAQ in NASDAQ stock exchange. Important intraday levels for the stock on upside are: 18 and 19 and 21 If the stock moves up, then it will find resistance near these levels.Instagram:https://instagram. lyft nasdaqpdi newstop option trading platformpro calendar Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.Financial highlights. Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share (including non-cash share-based compensation expense of $4.1 million), compared with $21.2 million or $0.50 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $3.1 million).Web mcomtop performing stock today COMPASS Pathways PLC Sponsored ADR (CMPS Quick Quote CMPS - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective.Recently, CMPS's ...May 25, 2021 · Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ... tech startup stocks In September of 2020, at $17 per share, Compass Pathways stock completed its public offering. Since the initial offering, CMPS has traded as high as $60 per share and seems to average out in the ...CMPS stock has been performing well on August 16, 2023, with positive price forecasts and a consensus among analysts to buy the stock. According to data from CNN Money, the 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 21.00.Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...Web